Identification of transcriptomics biomarker for the early prediction of critically ill COVID-19 patients
Author:
Chen Yong1, zhang Wenbo1, Yu Yonglin1, Chen Xiaoju2, Jiang Guolu1, Ou Guochun3, Liu Qin1, Jiang Li1, Chen Jianjun1
Affiliation:
1. The Affiliated Hospital of North Sichuan Medical College 2. Clinical Medical College & Affiliated Hospital of Chengdu University 3. Suining Central Hospital
Abstract
Abstract
Objective
Identifying the biological subsets of severe COVID-19 could provide a basis for finding biomarkers for the early prediction of the prognosis of severe COVID-19 and poor prognosis, and may facilitate specific treatment for COVID-19.
Methods
In this study we downloaded microarray dataset GSE172114 from the Gene Expression Omnibus (GEO) database in NCBI, and screened differentially-expressed genes (DEGs) by using the limma package in R software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted, and the results were presented by volcano, Venn, heat, and enrichment pathway bubble maps in the R language package. Gene set enrichment analysis (GSEA) was used to explore and demonstrate the signal pathways related to severe COVID-19. Protein-Protein Interaction (PPI) Network analysis and visualization were performed by using STRING and Cytoscape. Seven key protein expression molecules were screened by the MOCDE plug-in. Then, the cytoHubba plug-in was used to screen 10 candidate genes with maximal clique centrality (MCC) algorithm as the standard, and the intersection with the Venn diagram was used to obtain seven Hub genes. Receiver operating characteristic (ROC) curves were drawn to determine the area under the curve (AUC), and the predictive value of the key genes was evaluated.
Results
A total of 210 DEGs were identified, including 186 upregulated genes as well as downregulated ones. GO enrichment and KEGG pathway analysis were used, and the results were presented by volcano, Venn, heat, and enrichment pathway bubble maps in the R language package. Gene set enrichment analysis (GSEA) was used to explore and demonstrate the signal pathways related to severe COVID-19. Protein interaction network (PPI) analysis and visualization were performed by using STRING and Cytoscape. Seven key protein expression molecules were screened by the MOCDE plug-in. Then, the cytoHubba plug-in was used to screen 10 candidate genes with maximal clique centrality (MCC) algorithm as the standard, and the intersection with the Venn diagram was used to obtain seven Hub genes. Receiver operating characteristic (ROC) curves were drawn to determine the area under the curve (AUC), and the predictive value of the key genes was evaluated. The AUC of the PLSCR1 gene was 0.879, which was the most significantly upregulated key gene in critically ill COVID-19 patients.
Conclusions
Based on bioinformatics analysis, we found that the screened candidate gene, PLSCR1, may be closely related to the occurrence of severe COVID-19, and can thus be used for the early prediction of patients with severe COVID-19, and may provide meaningful research direction for their treatment.
Publisher
Research Square Platform LLC
Reference51 articles.
1. 1. Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, Embaireeg A, Almelahi M, Adel M, Dawoud ME, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. Int J Infect Dis 2021, 103:439–446. 2. 2. Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zhao Z, Jaffre F, et al. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell 2020, 27(1):125–136 e127. 3. 3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579(7798):270–273. 4. 4. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath S, Wurfel MM, Evans L, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med 2020, 382(21):2012–2022. 5. 5. Kreye J, Reincke SM, Kornau HC, Sanchez-Sendin E, Corman VM, Liu H, Yuan M, Wu NC, Zhu X, Lee CD, et al. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. Cell 2020, 183(4):1058–1069 e1019.
|
|